Levetiracetam Tablet, Extended Release
Product Images NDC 68180-118

9 FDA label images from Lupin Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68180-118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Molecular Structure-levetiracetam (8690e365 04d0 44ee 98ec 281e438ee0b0 01)

Molecular Structure-levetiracetam (8690e365 04d0 44ee 98ec 281e438ee0b0 01)
Chemical structure of levetiracetam, the active ingredient in Levetiracetam extended-release tablets. The diagram shows a pyrrolidone ring bonded to an ethyl group, a hydrogen atom, and a carboxamide group.*
FDA Label Image

Figure 1 (8690e365 04d0 44ee 98ec 281e438ee0b0 02)

Figure 1 (8690e365 04d0 44ee 98ec 281e438ee0b0 02)
Bar chart depicting the percentage of patients in three groups: placebo (7.4%), immediate-release levetiracetam 1000 mg/day (37.1%), and immediate-release levetiracetam 3000 mg/day (39.6%). Statistical significance versus placebo is indicated with asterisks for both levetiracetam groups.*
FDA Label Image

Figure 2 (8690e365 04d0 44ee 98ec 281e438ee0b0 03)

Figure 2 (8690e365 04d0 44ee 98ec 281e438ee0b0 03)
Bar chart showing the percentage of patients in three groups: placebo, immediate-release levetiracetam 1000 mg/day, and immediate-release levetiracetam 2000 mg/day. The chart highlights statistically significant differences versus placebo, with patient percentages of 6.3%, 20.8%, and 35.2%, respectively.*
FDA Label Image

Figure 3 (8690e365 04d0 44ee 98ec 281e438ee0b0 04)

Figure 3 (8690e365 04d0 44ee 98ec 281e438ee0b0 04)
A bar chart comparing the percentage of patients between a placebo group and an immediate-release levetiracetam group (3000 mg/day). The placebo group (N=104) shows 14.4% of patients, while the immediate-release levetiracetam group (N=180) shows 39.4%, marked as statistically significant versus placebo.*
FDA Label Image

Figure 4 (8690e365 04d0 44ee 98ec 281e438ee0b0 05)

Figure 4 (8690e365 04d0 44ee 98ec 281e438ee0b0 05)
A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6% and Immediate-release levetiracetam (N=101) with 44.6%. An asterisk indicates a statistically significant difference versus placebo.*
FDA Label Image

Image (E14df7b0 C752 4aeb A95c Ff6687a172ad 437 1)

Image (E14df7b0 C752 4aeb A95c Ff6687a172ad 437 1)
Levetiracetam extended release oral tablets packaging label from Lupin Pharmaceuticals, Inc. The image shows parts of packaging displaying 500 mg and 750 mg strengths. The label includes the product name Levetiracetam and indicates it as an extended release tablet form.*
FDA Label Image

Image (E14df7b0 C752 4aeb A95c Ff6687a172ad 557 1)

Image (E14df7b0 C752 4aeb A95c Ff6687a172ad 557 1)
Levetiracetam 500 mg extended-release oral tablets packaging label from Lupin Pharmaceuticals, Inc. The label features the brand and generic name, dosage strength, and manufacturer's name with a distinctive design element in black and white on the packaging.*
FDA Label Image

Conatiner Label 500 mg-bottle Of 60 Tablets (8690e365 04d0 44ee 98ec 281e438ee0b0 06)

Conatiner Label 500 mg-bottle Of 60 Tablets (8690e365 04d0 44ee 98ec 281e438ee0b0 06)
Levetiracetam Extended-Release Tablets USP 500 mg oral tablets label by Lupin Pharmaceuticals, Inc. The label indicates a 60-tablet bottle, with once daily dosing and Rx only. Manufactured by Lupin Limited, India, it includes storage instructions and a QR code link for the medication guide.*
FDA Label Image

Conatiner Label 750 mg-bottle Of 60 Tablets (8690e365 04d0 44ee 98ec 281e438ee0b0 07)

Conatiner Label 750 mg-bottle Of 60 Tablets (8690e365 04d0 44ee 98ec 281e438ee0b0 07)
Levetiracetam Extended-Release Tablets USP 750 mg label for oral tablets. The label indicates a package of 60 extended-release tablets for once daily dosing. It is manufactured by Lupin Pharmaceuticals, Inc., and includes storage instructions and a QR code linking to the Medication Guide. The label includes the NDC 68180-118-07.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.